Identification | Back Directory | [Name]
(5Z,8R,9R,10E,12S)-8-acetyl-9-formyl-12-hydroxyheptadeca-5,10-dienoic acid | [CAS]
91712-41-3 | [Synonyms]
LGE2 Levuglandin E2 levuglandin LGD2 (5Z,8R,9R,10E,12S)-8-acetyl-9-formyl-12-hydroxyheptadeca-5,10-dienoic acid (5Z,8R,9R,10E,12S)-8-Acetyl-12-hydroxy-9-formyl-5,10-heptadecadienoic acid | [Molecular Formula]
C20H32O5 | [MOL File]
91712-41-3.mol |
Hazard Information | Back Directory | [Description]
Levuglandin E2 is a secoprostanoid from prostaglandin endoperoxide; gamma-ketoaldehyde cpd; related to prostaglandin E2. | [Definition]
ChEBI:Levuglandin E2 is a levuglandin. | [in vitro]
Levuglandin E2 (LGE2), a rearrangement product derived from the prostaglandin endoperoxide, PGH2, causes repair-resistant DNA-protein cross-links and cell death (LD50 = 230 nM) in V79 Chinese hamster lung fibroblasts._x000D_
_x000D_
Reference: Biochemistry. 1993 Apr 20;32(15):4090-7. https://pubmed.ncbi.nlm.nih.gov/8471616/ | [in vivo]
Treatment of LDL with LGE2 (Levuglandin E2) leads to uptake and degradation by mouse peritoneal macrophages. Oxidized LDL, but not acetyl LDL efficiently competed for binding and uptake of LGE2-modified 125I-LDL. This result suggests that LGE2-modified LDL was recognized by a class of scavenger receptor that demonstrated ligand specificity for oxidized LDL but not for acetyl LDL._x000D_
_x000D_
Reference: Biochim Biophys Acta. 1997 Jan 7;1344(1):1-5. https://pubmed.ncbi.nlm.nih.gov/9022751/ | [target]
Levuglandin E2 is a secoprostanoid from prostaglandin endoperoxide. |
|
|